Consensus Statements on the Use of Novel Formulations of Isotretinoin: A Modified Delphi Process
Paige Kingston(Keck Hospital of USC), April W. Armstrong(University of Southern California), Linda Stein Gold(Henry Ford Health System), Julie Harper(Gold Skin Care Center), Leon Kircik(University School), Seemal R. Desai(The University of Texas Southwestern Medical Center), J.Q. Del Rosso(Valley Hospital Medical Center), Neal Bhatia, Firas G. Hougeir
Cited by 0
Related Papers
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*
|British Journal of Dermatology|2020|590
Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults
|Journal of the American Academy of Dermatology|2016|564
Deucravacitinib: A Novel TYK2 Inhibitor for the Treatment of Moderate-to-Severe Psoriasis
|Journal of Psoriasis and Psoriatic Arthritis|2023|25
Shared decision-making and satisfaction with care in patients with psoriasis: A population-based study in the United States
|Journal of the American Academy of Dermatology|2023|19
Vaccination recommendations for adults receiving biologics and oral therapies for psoriasis and psoriatic arthritis: Delphi consensus from the medical board of the National Psoriasis Foundation
|Journal of the American Academy of Dermatology|2024|19